IVERIC bio, Inc.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 compri…
Biotechnology
US, Parsippany [HQ]
Ratios
12 Sheets · Starting from 2022Margins, Growth Rates In %
| Ratio | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||
| Gross Margin | - - | - - | - - | 100.00 | 100.00 | 100.00 | 100.00 | - - | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | -237.98 | -205.26 | -379.93 | 54.39 | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | -195.14 | -239.84 | -384.14 | 51.44 | - - | - - | - - | - - | - - | |
|
EPS Growth
|
- - | 21.69 | -773.85 | 48.06 | -3.73 | -78.11 | 158.35 | -46.54 | -181.77 | 17.99 | 1.75 | -29.46 | |
| EPS USD | -83.00 | -65.00 | -568.00 | -295.00 | -306.00 | -545.00 | 318.00 | 170.00 | -139.00 | -114.00 | -112.00 | -145.00 | |
| Return on Assets (ROA) | -241.10 | -298.44 | -23.50 | -19.70 | -24.65 | -64.55 | 65.05 | 45.99 | -45.21 | -39.01 | -29.34 | -26.36 | |
| Return on Equity (ROE) | -424.49 | 152.79 | -30.13 | -66.74 | -176.35 | 204.42 | 300.22 | 50.89 | -50.24 | -44.16 | -31.69 | -32.86 | |
| Return on Invested Capital (ROIC) | -423.88 | -883.33 | -26.71 | -79.20 | -177.82 | 206.26 | 296.14 | -53.62 | -51.76 | -44.35 | -31.48 | -28.44 | |
| Solvency | |||||||||||||
| Equity Ratio | - - | -100 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | 226.26 | - - | -4.58 | - - | - - | - - | - - | 0.38 | 0.05 | 0.40 | 14.66 | |
| Debt/Equity | - - | -115.83 | - - | -15.50 | - - | - - | - - | - - | 0.42 | 0.06 | 0.44 | 18.28 | |
| Debt/EBITDA | 32.58 | -48.03 | 423.98 | 49.66 | 182.14 | 69.37 | -148.74 | -210.91 | 204.34 | 74.67 | 226.46 | 196.87 | |
|
Debt/Capitalization
|
- - | 731.56 | - - | -18.35 | - - | - - | - - | - - | 0.42 | 0.06 | 0.43 | 15.46 | |
| Long-Term Debt/Capitalization | - - | - - | - - | -18.35 | - - | - - | - - | - - | - - | 0.03 | 0.17 | 15.30 | |
| Interest Debt per Share USD | - - | 0.51 | 0.16 | -0.68 | 0.03 | 0.05 | 0.04 | 0.06 | 0.06 | 0.01 | 0.02 | 0.83 | |
| Debt Growth | - - | - - | -100.00 | - - | - - | - - | - - | - - | - - | -76.77 | 1,266.09 | 6,123.30 | |
| Liquidity | |||||||||||||
| Current Ratio | 224.54 | 33.57 | 3,453.53 | 2,388.31 | 817.18 | 448.87 | 1,368.21 | 1,009.29 | 990.63 | 861.93 | 1,373.54 | 1,862.55 | |
| Quick Ratio | 222.61 | 29.87 | 3,345.45 | 2,342.39 | 802.51 | 444.20 | 1,343.11 | 1,020.22 | 974.90 | 842.87 | 1,353.19 | 1,817.62 | |
| Cash Ratio | 191.57 | 29.87 | 3,345.45 | 200.77 | 591.55 | 203.18 | 1,332.05 | 993.50 | 968.11 | 264.12 | 926.76 | 1,338.42 | |
| Operating Cash Flow Ratio | -500 | - - | -700 | 500 | -200 | -100 | -900 | -300 | -300 | -200 | -300 | -400 | |
| Turnover | |||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | 4,297.81 | 1,173.50 | 1,441.77 | 15,138.93 | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Asset Turnover
|
- - | - - | - - | 8.28 | 12.01 | 16.99 | 119.59 | - - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | 2,653.31 | 1,486.01 | 1,551.63 | 40,536.10 | - - | - - | - - | - - | - - | |
| Coverage | |||||||||||||
| Interest Coverage | - - | -2,695.68 | -3,261.69 | -37,102.76 | -12,721.73 | -11,476.76 | 7,096.25 | -2,735.41 | -2,848.54 | -17,747.20 | - - | -8,388.07 | |
| Asset Coverage | - - | - - | - - | - - | - - | - - | - - | - - | 23,700 | 166,600 | 23,000 | 600 | |
| Cash Flow Coverage (CFGR) | - - | -118.70 | - - | -487.06 | - - | - - | - - | - - | -9,795.96 | -57,475.65 | -6,273.65 | -167.51 | |
| EBITDA Coverage | - - | -2,700 | -3,400 | -36,900 | -12,500 | -11,300 | 7,300 | 2,600 | -2,800 | -17,700 | - - | -8,400 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | 200 | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||||||
| Dividend Yield | - - | - - | 2.02 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -3.15 | -2.46 | -17.56 | -6.58 | -3.89 | -112.85 | 101.91 | 141.75 | -16.25 | -16.49 | -6.71 | -6.78 | |
|
Price/Earnings (P/E)
|
-3,176.99 | -4,061.98 | -569.45 | -1,519.83 | -2,568.71 | -88.61 | 98.13 | 70.55 | -615.51 | -606.31 | -1,490.92 | -1,474.52 | |
| Price/Earnings Growth (PEG) | - - | 187.30 | -0.74 | 31.62 | -688.88 | -1.13 | -0.62 | -1.52 | 3.39 | 33.71 | 849.83 | -50.04 | |
|
Price/Book (P/B)
|
13,485.91 | -6,206.32 | 171.60 | 1,014.33 | 4,529.95 | -181.15 | 294.60 | 35.90 | 309.24 | 267.73 | 472.45 | 484.60 | |
| Price/Tangible Book (P/TB) | 13,485.91 | -6,206.32 | 171.60 | 1,014.33 | 4,529.95 | -181.15 | 294.60 | 35.90 | 309.24 | 267.73 | 472.45 | 484.60 | |
| Price/Sales (P/S) | - - | - - | - - | 3,616.88 | 5,272.43 | 336.67 | 53.37 | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-3,095.58 | -4,513.99 | -597.12 | 1,343.34 | -3,457.96 | -157.83 | -91.99 | -106.19 | -747.13 | -775.55 | -1,728.10 | -1,582.33 | |
| Price/Free CF (P/FCF) | -3,094.93 | -4,513.99 | -597.06 | 1,363.65 | -3,346.52 | -157.00 | -91.99 | -106.19 | -747.13 | -775.55 | -1,721.79 | -1,575.25 | |
| Price/Operating CF (P/OCF) | -3,095.58 | -4,513.99 | -597.12 | 1,343.34 | -3,457.96 | -157.83 | -91.99 | -106.19 | -747.13 | -775.55 | -1,728.10 | -1,582.33 |